23.01.2013 • NewsJoerg ReinhardtNovartisBayer

Dr. Joerg Reinhardt to Leave Bayer HealthCare

Dr. Joerg Reinhardt (56), Chairman of the Board of Management of Bayer HealthCare and a member of the Bayer Executive Council, will not renew his contract when it expires in summer 2013. Instead he intends to stand for election as new Director of Swiss healthcare company Novartis and designated non-executive Chairman of the Board at its annual general meeting to be held at the end of February with a view to assuming that office on August 1, 2013. Reinhardt will end his active service with Bayer effective February 28, 2013.

Bayer Management Board member Prof. Wolfgang Plischke (61), whose responsibilities currently include Technology, Innovation and Sustainability, will take over the function of Chairman at Bayer HealthCare in addition to his existing duties until a successor is appointed. Prior to his appointment to the Bayer Board of Management on March 1, 2006, Plischke had worked in the health care field for 25 years, latterly as General Manager of what was then the Pharmaceuticals Business Group.

Joerg Reinhardt has been Chairman of the Board of Management of Bayer HealthCare since August 15, 2010. In April 2012, Reinhardt was appointed to the Board of Directors of Lonza Group, Basel, Switzerland. Lonza is a global company that provides products and services for the life sciences industry. Reinhardt is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.